Back to top
more

Aurora Cannabis (ACB)

(Real Time Quote from BATS)

$5.06 USD

5.06
63,029

-0.03 (-0.59%)

Updated Oct 28, 2025 10:02 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.16%
3Hold10.10%
4Sell5.63%
5Strong Sell2.84%
S&P50011.45%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 243)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sundeep Ganoria headshot

How to Play Aurora Cannabis Stock Amid Renewed Legalization Hopes?

by Sundeep Ganoria

Aurora Cannabis gains 21% as its medical segment fuels revenue and margin growth, even as recreational sales drag.

Sundeep Ganoria headshot

Should You Buy TLRY Stock After Encouraging Q1 Results?

by Sundeep Ganoria

Tilray's return to profitability, stronger cash flow, and expanding global cannabis and beverage operations highlight its renewed growth story.

Sundeep Ganoria headshot

Should You Buy or Sell CURLF Stock Amid Renewed Legalization Hopes?

by Sundeep Ganoria

Curaleaf's shares have soared over 200% on renewed legalization optimism, but domestic weakness and profit hurdles cloud the outlook.

Zacks Equity Research

Aurora Cannabis (ACB) Soars 6.2%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Aurora Cannabis (ACB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Implied Volatility Surging for Aurora Cannabis Stock Options

by Zacks Equity Research

Investors need to pay close attention to ACB stock based on the movements in the options market lately.

Sundeep Ganoria headshot

Here's Why JAZZ Stock Is an Unconventional Cannabis Investment

by Sundeep Ganoria

Jazz Pharma is redefining cannabis investing with Epidiolex, a fast-growing FDA-approved epilepsy drug fueling its growth.

Sridatri Sarkar headshot

Retail Expansion Positions High Tide for Long-Term Growth

by Sridatri Sarkar

HITI expands Canna Cabana to 203 stores, boosting market share and outpacing peers with 2.3X revenue per location.

Sundeep Ganoria headshot

Cannabis Stock VRNOF Soars 178% in a Month: Time to Buy, Sell or Hold?

by Sundeep Ganoria

Verano's stock has surged 178% in a month on reform hopes, but pricing pressure and stiff competition test its momentum.

Sweta Killa headshot

Cannabis ETFs Soar as Trump Mulls Over Marijuana Reclassification

by Sweta Killa

Cannabis ETFs like WEED, CNBS and MJ surge after Trump confirmed that his administration is weighing marijuana's move from Schedule I to Schedule III.

Zacks Equity Research

ACB Stock Down as Q1 Earnings Miss Estimates, Revenues Up Y/Y

by Zacks Equity Research

Aurora Cannabis stock slips after Q1 earnings miss, but revenue climbs 17.5% year over year on strong global medical cannabis demand.

Zacks Equity Research

Aurora Cannabis Inc. (ACB) Reports Q1 Loss, Beats Revenue Estimates

by Zacks Equity Research

Aurora Cannabis (ACB) delivered earnings and revenue surprises of -205.56% and +6.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Jushi Holdings Inc. (JUSHF) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Jushi Holdings Inc. (JUSHF) delivered earnings and revenue surprises of 0.00% and +0.33%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aurora Cannabis Pre-Q1 Earnings Analysis: Buy, Sell or Hold the Stock?

by Zacks Equity Research

ACB's global medical cannabis momentum stays strong, but near-term regulatory headwinds might have limited Q1 revenue upside.

Zacks Equity Research

Do Options Traders Know Something About Aurora Cannabis Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to ACB stock based on the movements in the options market lately.

Sundeep Ganoria headshot

Should You Buy, Hold or Sell TLRY Stock Post Q4 Earnings Release?

by Sundeep Ganoria

Tilray posts record non-cannabis revenues in fiscal 2025, but Q4 sales slip as cannabis weakness pressures overall results.

Sundeep Ganoria headshot

Cannabis Operator Green Thumb Down 30% YTD: Time to Buy, Sell or Hold?

by Sundeep Ganoria

GTBIF slides 30% YTD as rising costs, flat revenues and tight U.S. rules weigh on margins and investor sentiment.

Sundeep Ganoria headshot

Cannabis Stock Cresco Labs Plunges 24% YTD: Time to Sell or Hold?

by Sundeep Ganoria

CRLBF is down 24% YTD as U.S.-only exposure, falling margins and tighter regulations weigh on its cannabis business.

Sundeep Ganoria headshot

Cannabis Operator Curaleaf Plunges 46% YTD: Time to Sell or Hold?

by Sundeep Ganoria

CURLF dives 46% YTD as domestic headwinds outweigh global growth; is it time to cash out or wait for a rebound?

Zacks Equity Research

Aurora Cannabis Inc. (ACB) Misses Q4 Earnings Estimates

by Zacks Equity Research

Aurora Cannabis (ACB) delivered earnings and revenue surprises of -36.36% and 1.65%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

High Tide Inc. (HITI) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

High Tide (HITI) delivered earnings and revenue surprises of -50% and 0.22%, respectively, for the quarter ended April 2025. Do the numbers hold clues to what lies ahead for the stock?

Sundeep Ganoria headshot

Cannabis Stock CGC Rallies 39% in Three Months: Time to Buy or Sell?

by Sundeep Ganoria

Canopy Growth surges 39% in three months as restructuring, margin gains and debt cuts renew investor interest.

Sundeep Ganoria headshot

Cannabis Operator VFF Sells Fresh Produce Unit: How to Play the Stock?

by Sundeep Ganoria

After dropping its produce business, Village Farms sharpens its cannabis focus - boosting exports, margins and market share.

Sundeep Ganoria headshot

Aurora Cannabis Stock Rises 30% YTD: Time to Buy or Sell?

by Sundeep Ganoria

ACB's 30% YTD rally reflects Q3 strength, but flat EPS estimates and consumer weakness keep analysts cautious about long-term upside.

Zacks Equity Research

Canopy Growth Corporation (CGC) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Canopy Growth (CGC) delivered earnings and revenue surprises of -840% and 9.41%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Agilent Technologies (A) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Agilent (A) delivered earnings and revenue surprises of 3.97% and 2.64%, respectively, for the quarter ended April 2025. Do the numbers hold clues to what lies ahead for the stock?